Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202412339

The Syndemic of Chronic Pain: A Narrative Review of an Integrated Care Model from Community-Based Management to Interventional Anesthesia and Public Health Surveillance

Hassan Ibrahim Abdo Fath [(1)] , Mhammmed Quayyid Almutairi [(2)] , Yahia Abdullah Monawar Mubarak [(3)] , Wadyan Saud Awn Aljameeli [(4)] , Meshal Abdullah Alhilfi [(5)] , Ali Mohammed Al Amer [(6)] , Omar Murdhi Alanazi [(7)] , Ibtihal A. Alyami [(8)] , Ali Waleed Khalafallah [(9)] , Sami Mutlaq Aldughaylibi [(10)] , Saad Sanaitan Almutairi [(11)] , Ibrahim Ahmed Ibrahim Arawi [(12)] , Taib Husain Marir [(12)]

(1) Abu Arish North Center,Ministry of Health, Saudi Arabia,
(2) Al Ghailana Health Center,Ministry of Health, Saudi Arabia,
(3) Samtah General Hospital, Ministry of Health, Saudi Arabia,
(4) Maternity & Children's Hospital, Hafr Al-Batin,Ministry of Health, Saudi Arabia,
(5) Prince Mohammed Bin Abdulaziz Hospital,Ministry of Health, Saudi Arabia,
(6) Al Ha'ir Health Center,Ministry of Health, Saudi Arabia,
(7) Extended Care Hospital (Formerly Convalescence) In Riyadh,Ministry of Health, Saudi Arabia,
(8) Ad Diriyah Hospital,Ministry of Health, Saudi Arabia,
(9) Prince Salman Bin Mohammed Hospital – Ballam,Ministry of Health, Saudi Arabia,
(10) Tumair Hospital, Ministry of Health, Saudi Arabia,
(11) Ministry Of Health, Saudi Arabia,
(12) Erada Mental Health Hospital,Ministry of Health, Saudi Arabia

Abstract

Background: Chronic pain, mental health disorders, and opioid misuse constitute a synergistic epidemic (syndemic) that overwhelms traditional, fragmented healthcare approaches. This complex interplay demands a fundamentally integrated care model spanning community-based management, specialized intervention, and population-level surveillance.

Aim: This narrative review aims to construct and advocate for a cohesive, multidisciplinary framework for addressing the chronic pain syndemic.

Methods: A comprehensive literature search was conducted across PubMed, Scopus, PsycINFO, and CINAHL databases for peer-reviewed articles published between 2010 and 2024. Search terms included combinations of "chronic pain," "syndemic," "opioid misuse," "integrated care," "multidisciplinary pain management," "public health surveillance," and relevant professional roles.

Results: The review identifies critical, interdependent functions for each discipline: Family Medicine and Nursing provide first-line biopsychosocial assessment and non-pharmacologic foundational care. Anesthesiology-led Pain Medicine offers advanced interventional procedures and complex pharmacotherapy. Pharmacy ensures medication safety through risk mitigation and therapy management. Public Health and Epidemiology provide essential surveillance data on opioid overdoses and population pain prevalence, while Health Safety addresses systemic prescribing safeguards and diversion prevention.

Conclusion: Effectively addressing the chronic pain syndemic is contingent upon dismantling care silos and implementing a proactive, patient-centered, and population-aware integrated model. Future efforts must focus on formalizing collaborative pathways, co-locating services, leveraging shared health informatics, and aligning policies to support this essential teamwork.

Keywords: chronic pain syndemic, integrated pain management, opioid stewardship, multidisciplinary care, public health surveillance.

Introduction

Chronic pain is a defining public health challenge of the 21st century, affecting approximately 20-30% of the global population and imposing staggering economic and social costs (Goldberg & McGee, 2011). However, to conceptualize it as an isolated clinical entity is a critical fallacy. Contemporary evidence reveals it exists within a syndemic—a term denoting synergistic, co-occurring epidemics that exacerbate the burden of disease through complex biological and socio-ecological interactions (Singer et al., 2021). The chronic pain syndemic is fundamentally intertwined with highly prevalent mental health conditions, particularly depression and anxiety, and the iatrogenic crisis of prescription opioid misuse, addiction, and overdose (Volkow & McLellan, 2016). This triad creates a vicious cycle: pain begets psychological

*Corresponding author e-mail: Hfath@Moh.Gov.Sa (Hassan Ibrahim Abdo Fath).

Receive Date: 12 December 2024, Revise Date: 30 December 2024, Accept Date: 31 December 2024

distress, which lowers pain tolerance and compromises coping, potentially leading to escalated medication use, which in turn carries risks of misuse and adverse outcomes (Cheatle, 2015).

Traditional, fragmented healthcare delivery is profoundly ill-equipped to manage this complexity. The predominant model often relegates management to isolated encounters in primary care, where time constraints limit holistic assessment, or to pain clinics with long wait times, fostering a disjointed journey for patients (Dowell et al., 2016). This fragmentation contributes to the over-reliance on pharmacotherapy, particularly opioids, as a seemingly straightforward solution, while under-utilizing evidence-based multimodal strategies (Busse et al., 2018). The consequences are visible in the stark statistics of the opioid crisis, which, despite recent policy shifts, continues to claim tens of thousands of lives annually, frequently involving prescription medications (CDC, 2023).

Addressing this syndemic, therefore, requires a paradigm shift from siloed intervention to integrated care. This model must seamlessly connect community-based first-line management with specialized interventional expertise, all underpinned by robust public health surveillance and systemic safety mechanisms. This narrative review synthesizes literature from 2010 to 2024 to construct such a model. It will delineate the indispensable and collaborative roles of Family Medicine and Nursing, Anesthesiology-based Pain Medicine, Pharmacy, Public Health/Epidemiology, and Health Safety professionals. By mapping their integrated functions across the care continuum—from prevention and early management to advanced intervention and population-level monitoring—this review argues that only through deliberate, systemic collaboration can we effectively alleviate suffering, restore function, and mitigate the broader societal harms of the chronic pain syndemic.

First-Line Biopsychosocial Management in Family Medicine and Nursing

The journey through the chronic pain syndemic most commonly begins in primary care, making Family Medicine practitioners and affiliated Nursing staff the cornerstone of the integrated model. Their role extends far beyond simple diagnosis and prescription; it is the initiation of a longitudinal, patient-centered, biopsychosocial partnership.

The initial encounter must actively deconstruct the syndemic by concurrently assessing pain, mental health, and substance use risk. This requires moving beyond a purely somatic evaluation to employ validated tools for assessing pain interference (e.g., PEG scale), screening for depression and anxiety (e.g., PHQ-2/9, GAD-7), and evaluating risk for opioid misuse (e.g., Opioid Risk Tool, COMM for current patients) (Kroenke et al., 2021; Finkelman et al., 2020). Nursing professionals are pivotal in administering these screenings, conducting focused histories, and providing essential patient education, thereby extending the reach and depth of the clinical assessment (Compton & St Marie, 2021).

First-line management must explicitly prioritize non-pharmacologic strategies, establishing them as the foundation of care rather than adjuncts. Family physicians and nurses are ideally positioned to initiate and champion these approaches. This includes structured education on pain neuroscience, promoting paced activity, and prescribing exercise—one of the most evidence-based interventions for chronic musculoskeletal pain (Geneen et al., 2017). Furthermore, they can initiate basic cognitive-behavioral therapy (CBT) principles, refer to physiotherapy and occupational therapy, and guide patients towards mindfulness-based stress reduction (MBSR), all of which have strong efficacy (Cherkin et al., 2016; Qaseem et al., 2017).

When pharmacotherapy is indicated, the primary care team's approach must be guided by a "start low, go slow" philosophy, with a clear hierarchy. Acetaminophen and NSAIDs are first-line for appropriate pain types, with careful attention to comorbidities (Dowell et al., 2016). If opioids are considered for moderate-to-severe pain unresponsive to other therapies, their initiation is a high-stakes event. It mandates a formal shared decision-making process, including a discussion of risks and realistic benefits, and the establishment of a treatment agreement (or "pain contract") outlining expectations, safe use, and conditions for continued prescribing (Rosenberg et al., 2018). The primary care team's longitudinal relationship allows for ongoing monitoring of treatment response, functional goals, and adherence to the agreement, forming the first critical layer of opioid stewardship.

The Role of Anesthesiology and Pain Medicine Specialists

When pain persists despite comprehensive primary care management, or when it presents with complex features (e.g., severe neuropathic pain, radiculopathy, centralized pain states), referral to a specialist in Pain Medicine—often an anesthesiologist with sub-specialty training—becomes essential. This transition should not represent an abrogation of primary care responsibility but a strategic escalation within the integrated team.

The pain medicine specialist conducts a sophisticated re-evaluation, often bringing advanced diagnostic acumen, particularly for nociceptive versus neuropathic pain generators, and consideration of maladaptive central nervous system sensitization (Cohen & Mao, 2014). They are instrumental in optimizing complex pharmacologic regimens, which may include judicious opioid rotation, initiation of adjuvant medications like gabapentinoids, SNRIs (e.g., duloxetine), or tricyclic antidepressants, and

management of polypharmacy (Finnerup et al., 2015). Their expertise is crucial for patients on long-term opioid therapy, assisting in dose stabilization, risk mitigation, and, when appropriate, supervised dose tapering—a process fraught with challenges that benefits from specialist oversight (Frank et al., 2016).

A defining contribution of the interventional anesthesiologist is the provision of targeted procedural therapies. These are not curative but can be powerful tools for breaking pain cycles, reducing analgesic burden, and facilitating engagement in rehabilitation. Examples include epidural steroid injections for radicular pain, radiofrequency ablation for facet-mediated pain, spinal cord stimulation for failed back surgery syndrome, and joint or peripheral nerve blocks (Manchikanti et al., 2017). The decision to pursue intervention is made collaboratively with the patient and referring provider, with clear goals defined (e.g., reduce pain by 50% to enable physiotherapy).

Crucially, the pain specialist's role in the integrated model is not to assume perpetual care but to function as a consultant. The goal is to conduct an intensive assessment, implement a specialized phase of treatment (procedural or pharmacologic), and then return the patient to the primary care team with a refined management plan and clear recommendations. This "bridge" function is vital for continuity and prevents the creation of yet another silo.

The Central Role of Pharmacy

Pharmacists are the medication safety experts essential to navigating the pharmacological minefield of the chronic pain syndemic. Their role spans direct patient care, prescriber support, and system-level quality improvement, forming the backbone of opioid stewardship programs within the integrated model.

At the patient level, pharmacists provide Medication Therapy Management (MTM), a critical service for complex pain patients. This includes comprehensive medication reconciliation to avoid dangerous interactions, counseling on safe opioid use (storage, disposal, avoidance of alcohol and benzodiazepines), and education on the appropriate use of rescue medications (Cochran et al., 2017). Community pharmacists, in particular, are accessible frontline professionals who can monitor fill patterns, identify early signs of misuse (e.g., early refills, lost prescriptions), and provide naloxone kits and training to patients and families—a key overdose prevention strategy (Green et al., 2017).

At the prescriber and system level, pharmacists are invaluable collaborators. They can assist in calculating morphine milligram equivalents (MMEs), reviewing Prescription Drug Monitoring Program (PDMP) data, and advising on opioid rotation and tapering schedules (Dowell et al., 2016). In clinic-based models, embedded clinical pharmacists can conduct proactive patient reviews, manage therapy agreements, and handle time-consuming monitoring tasks, thereby extending the capacity of the physician (Rossom et al., 2023). Furthermore, pharmacists lead in developing and implementing institutional guidelines for opioid prescribing, ensuring alignment with best practice recommendations and mitigating inappropriate variability.

Pharmacy also plays a defensive role in diversion prevention. Pharmacists are gatekeepers who must verify prescription legitimacy, recognize forged scripts, and adhere to dispensing regulations. Their vigilance is a final, crucial check in the controlled substance supply chain (Gudin et al., 2013). By integrating pharmacy expertise directly into the pain management team, safety is embedded into every step of the medication use process.

Surveillance, Data, and Policy by Public Health and Epidemiology

While clinicians manage individuals, Public Health and Epidemiology professionals monitor the collective, providing the indispensable macro-view of the syndemic. Their work translates population-level data into actionable intelligence that shapes clinical guidelines, resource allocation, and policy.

A core function is surveillance. Public health agencies track key indicators such as opioid prescribing rates (e.g., MMEs per capita), prevalence of non-fatal opioid overdoses treated in emergency departments, and, most critically, opioid-involved overdose mortality (Rossen et al., 2021). Epidemiologists analyze this data to identify high-risk geographic areas, demographic trends, and the evolving impact of illicitly manufactured fentanyl (Jalal et al., 2018). This surveillance is not passive; it directly informs clinical practice by highlighting the consequences of prescribing patterns and the shifting external drug environment.

Furthermore, public health research characterizes the population prevalence and burden of chronic pain itself, examining its societal costs, disparities in access to care, and its intersection with social determinants of health (Dahlhamer, 2018). This data is vital for advocating for resources, designing equitable interventions, and demonstrating that pain is not merely a clinical complaint but a widespread societal burden.

Public health also drives community-level interventions that support the integrated model. This includes funding and promoting community naloxone distribution programs, supporting syringe service programs to prevent infectious disease among those with substance use disorder, and launching public education campaigns to destigmatize pain and addiction and promote safe prescribing and disposal practices (Davis & Carr, 2017). By addressing the syndemic's roots in the community environment, public health creates a context in which clinical interventions can be more effective.

Health Safety, Security, and Prescribing Infrastructure

The final pillar of the integrated model involves designing systems that make safe practice the default and mitigate risks of diversion. This is the

domain of Health Safety and Security professionals, often working in healthcare administration, compliance, and informatics (Table 1).

A cornerstone intervention is the robust implementation and mandatory use of Prescription Drug Monitoring Programs (PDMPs). These state-run electronic databases track controlled substance prescriptions. Health safety mandates ensure clinicians query the PDMP before issuing an opioid prescription, a practice shown to reduce "doctor shopping" and inappropriate prescribing (Haffajee et al., 2015). However, integration must go beyond mandate; PDMP data should be seamlessly embedded within the electronic health record (EHR) workflow to minimize clinician burden.

The EHR itself is a critical safety tool. Health safety experts collaborate with clinicians to build safer prescribing systems. This includes creating hard stops or alerts for prescriptions exceeding recommended MME thresholds, requiring co-prescription of naloxone for high-risk patients, enforcing the inclusion of diagnosis codes and treatment agreements, and facilitating easy referral templates to specialists (Ozturk et al., 2021; Smith et al., 2023). These "nudges" within the clinical workflow standardize care and reduce cognitive errors.

Furthermore, health safety addresses physical security and diversion prevention within healthcare facilities. This involves developing protocols for the secure storage and handling of controlled substances in clinics and pharmacies, establishing procedures for waste disposal, and investigating internal diversion incidents (Gudin et al., 2013). By securing the supply chain from manufacturer to patient, they protect both the public and the institution. Figure 1 illustrates a multidisciplinary healthcare integration framework highlighting coordinated interactions among clinical providers, nursing services, pharmacy, allied health professionals, and health information systems.

Table 1: The Integrated Care Team: Roles and Collaborative Functions in the Chronic Pain Syndemic

Specialty/Discipline	Core Functions	Key Collaborative Actions	Syndemic Target
Family Medicine & Nursing	Biopsychosocial assessment; First-line non-pharmacologic management; Initiation & monitoring of pharmacotherapy; Longitudinal relationship building.	Conducts initial syndemic screening; Refers to pain specialists & community resources; Manages treatment agreements; Provides continuous patient education.	Pain, Mental Health, Opioid Risk (Primary Prevention)
Anesthesia / Pain Medicine	Advanced diagnosis & phenotyping; Complex pharmacotherapy management; Interventional procedures; Supervised opioid tapering.	Accepts structured referrals from primary care; Returns patients with a refined plan; Consults on complex pharmacotherapy; Provides procedural "bridges."	Severe/Complex Pain, High-Risk Pharmacotherapy
Pharmacy	Medication Therapy Management (MTM); Opioid stewardship; PDMP review; Naloxone dispensing & education; Diversion prevention.	Embedded MTM in clinics; Advises on dosing, rotation, tapering; Proactively reviews PDMP data; Trains patients on safety.	Opioid Misuse, Medication Safety, Overdose Prevention
Public Health / Epidemiology	Opioid overdose surveillance; Population pain prevalence studies; Policy analysis & guideline development; Community education campaigns.	Provides data on local overdose trends; Identifies disparities in care access; Informs clinical guidelines with population data.	Population-Level Opioid Harm, Health Equity, Public Awareness
Health Safety & Security	PDMP system implementation & enforcement; EHR safety design (alerts, hard stops); Secure medication storage protocols; Diversion investigation.	Integrates PDMP into EHR workflow; Builds prescribing safeguards; Secures institutional controlled substance supply chain.	Systemic Prescribing Risk, Diversion Prevention

Challenges to Integration and Future Directions

Despite the compelling rationale, significant barriers impede the implementation of this integrated model. Financial disincentives are paramount: Fee-for-service reimbursement often inadequately compensates for the time-intensive non-pharmacologic management, multidisciplinary consultation, and complex care coordination required

(DeBar et al., 2012). Workforce shortages, particularly in pain medicine, behavioral health, and pharmacy in rural areas, create access deserts. Stigmatizing attitudes toward both pain and addiction among providers and the public further hinder compassionate, evidence-based care (Kennedy et al., 2014). Finally, technological silos, where EHRs, PDMPs, and community service databases do not communicate, create frustrating administrative burdens that erode collaboration.

Figure 1: Conceptual Framework of Multidisciplinary Healthcare Integration

Future directions must address these barriers head-on. Payment reform is essential, promoting value-based bundled payments for chronic pain management that reward outcomes and team-based care (Katzman et al., 2014). Workforce development can be enhanced through expanded training in pain and addiction for all healthcare trainees and the use of telehealth to extend specialist reach. Co-location of services, such as embedding behavioral health clinicians and clinical pharmacists within primary care clinics, physically facilitates integration (Archer et al., 2012). Finally, investment in interoperable health information technology that seamlessly shares relevant data across the care continuum is a non-negotiable infrastructure requirement (Table 2). Figure 2 presents a schematic overview of how evidence-based interventions translate into improved patient and population health outcomes.

Figure 2: Pathways Linking Evidence-Based Interventions to Improved Health Outcomes

Table 2: Proposed Metrics for Evaluating an Integrated Chronic Pain Syndemic Model

Domain	Process Metrics	Outcome Metrics	Data Source
Access & Integration	% of patients screened for depression/anxiety at pain visits; Time from referral to pain specialist consult; Co-location of BH/Pharmacy in primary care.	Patient-reported experience of care coordination; No. of "warm handoff" referrals between team members.	EHR, Patient Surveys, Administrative Data
Quality of Care	% of opioid-naïve patients prescribed <50 MME/day; % of high-risk patients co-prescribed naloxone; PDMP query rate prior to opioid prescription.	Change in pain interference scores; Change in functional status (e.g., PROMIS); Rate of opioid-related adverse drug events.	EHR, PDMP, Patient-Reported Outcomes
Opioid Safety & Public Health	Community naloxone kit distribution rate; Prescribing rate of high-dose opioids (≥90 MME/day).	Opioid overdose deaths (prescription-involved); Rate of opioid use disorder diagnoses; ED visits for non-fatal overdose.	Public Health Surveillance, Vital Statistics, Claims Data
Economic	Cost per patient for an integrated care episode.	Healthcare utilization (ED visits, hospitalizations) for pain or overdose; Productivity metrics (return to work).	Claims Data, Employer Records

Conclusion

The chronic pain syndemic—the entangled crises of persistent pain, mental health comorbidity, and opioid-related harm—presents one of modern healthcare's most formidable challenges. A fragmented, siloed response is not merely suboptimal; it is iatrogenic, contributing to the very crisis it seeks to manage. This narrative review has synthesized current evidence to propose an Integrated Chronic Pain Syndemic Care Model. This model is not defined by a single location or specialty but by a continuum of collaborative functions: from the biopsychosocial foundation laid in Family Medicine and Nursing, through the advanced interventional and pharmacological expertise of Pain Medicine, underpinned by the medication safety stewardship of Pharmacy, informed by the population intelligence of Public Health and Epidemiology, and secured by the systemic safeguards of Health Safety.

The path forward requires moving from conceptual models to operational reality. It demands policy and payment reform that incentivizes team-based, non-procedural care; interdisciplinary education that breaks down professional biases; and health information technology designed for sharing, not siloing. By embracing integration, we can transform the care journey for individuals with chronic pain from a lonely, confusing, and often dangerous odyssey into a supported, coordinated, and evidence-informed pathway toward improved function, quality of life, and safety. In doing so, we address not just a collection of symptoms, but the profound human and societal burden of the syndemic itself.

References

1. Archer, J., Bower, P., Gilbody, S., Lovell, K., Richards, D., Gask, L., ... & Coventry, P. (2012). Collaborative care for depression and anxiety problems. *Cochrane Database of Systematic Reviews*, (10). https://doi.org/10.1002/14651858.CD006525.pub2
2. Busse, J. W., Wang, L., Kamaleldin, M., Craigie, S., Riva, J. J., Montoya, L., ... & Guyatt, G. H. (2018). Opioids for chronic noncancer pain: a systematic review and meta-analysis. *Jama*, *320*(23), 2448-2460. doi:10.1001/jama.2018.18472
3. Cheatle, M. D. (2015). Prescription opioid misuse, abuse, morbidity, and mortality: balancing effective pain management and safety. *Pain Medicine*, *16*(suppl_1), S3-S8. https://doi.org/10.1111/pme.12904
4. Cherkin, D. C., Sherman, K. J., Balderson, B. H., Cook, A. J., Anderson, M. L., Hawkes, R. J., ... & Turner, J. A. (2016). Effect of mindfulness-based stress reduction vs cognitive behavioral therapy or usual care on back pain and functional limitations in adults with chronic low back pain: a randomized clinical trial. *Jama*, *315*(12), 1240-1249. doi:10.1001/jama.2016.2323
5. Cochran, G., Gordon, A. J., Gellad, W. F., Chang, C. C. H., Lo-Ciganic, W. H., Lobo, C., ... & Donohue, J. M. (2017). Medicaid prior authorization and opioid medication abuse and overdose. *The American journal of managed care*, *23*(5), e164.
6. Cohen, S. P., & Mao, J. (2014). Neuropathic pain: mechanisms and their clinical implications. *Bmj*, *348*. https://doi.org/10.1136/bmj.f7656
7. Compton, P., & St Marie, B. (2021). Coexisting substance use disorder and chronic pain during COVID-19. *Pain Management Nursing*, *23*(1), 17. https://doi.org/10.1016/j.pmn.2021.08.011
8. Dahlhamer, J. (2018). Prevalence of chronic pain and high-impact chronic pain among adults—United States, 2016. *MMWR. Morbidity and mortality weekly report*, *67*. http://dx.doi.org/10.15585/mmwr.mm6736a2
9. Davis, C. S., & Carr, D. (2015). Legal changes to increase access to naloxone for opioid overdose reversal in the United States. *Drug and alcohol dependence*, *157*, 112-120. https://doi.org/10.1016/j.drugalcdep.2015.10.013
10. DeBar, L. L., Kindler, L., Keefe, F. J., Green, C. A., Smith, D. H., Deyo, R. A., ... & Feldstein, A. (2012). A primary care-based interdisciplinary team approach to the treatment of chronic pain utilizing a pragmatic clinical trials framework. *Translational behavioral medicine*, *2*(4), 523-530. https://doi.org/10.1007/s13142-012-0163-2
11. Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC guideline for prescribing opioids for chronic pain—United States, 2016. *Jama*, *315*(15), 1624-1645. doi:10.1001/jama.2016.1464
12. Finkelman, M. D., Jamison, R. N., Kulich, R. J., Butler, S. F., Smits, N., & Weiner, S. G. (2020). A comparison of short forms of the Screener and Opioid Assessment for Patients With Pain–Revised (SOAPP-R). *European Journal of Psychological Assessment*, *36*(2), 387.
13. Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., ... & Wallace, M. (2015). Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *The Lancet Neurology*, *14*(2), 162-173. https://doi.org/10.1016/S1474-4422(14)70251-0
14. Frank, J. W., Levy, C., Matlock, D. D., Calcaterra, S. L., Mueller, S. R., Koester, S., & Binswanger, I. A. (2016). Patients' perspectives on tapering of chronic opioid therapy: a qualitative study. *Pain medicine*, *17*(10), 1838-1847. https://doi.org/10.1093/pm/pnw078
15. Geneen, L. J., Moore, R. A., Clarke, C., Martin, D., Colvin, L. A., & Smith, B. H. (2017). Physical

activity and exercise for chronic pain in adults: an overview of Cochrane Reviews. *Cochrane database of systematic reviews*, (4). https://doi.org/10.1002/14651858.CD011279.pub3

16. Goldberg, D. S., & McGee, S. J. (2011). Pain as a global public health priority. *BMC public health*, *11*(1), 770. https://doi.org/10.1186/1471-2458-11-770
17. Green, T. C., Case, P., Fiske, H., Baird, J., Cabral, S., Burstein, D., ... & Bratberg, J. (2017). Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states. *Journal of the American Pharmacists Association*, *57*(2), S19-S27. https://doi.org/10.1016/j.japh.2017.01.013
18. Gudin, J. A., Mogali, S., Jones, J. D., & Comer, S. D. (2013). Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. *Postgraduate medicine*, *125*(4), 115-130. https://doi.org/10.3810/pgm.2013.07.2684
19. Haffajee, R. L., Jena, A. B., & Weiner, S. G. (2015). Mandatory use of prescription drug monitoring programs. *Jama*, *313*(9), 891-892. doi:10.1001/jama.2014.18514
20. Jalal, H., Buchanich, J. M., Roberts, M. S., Balmert, L. C., Zhang, K., & Burke, D. S. (2018). Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. *Science*, *361*(6408), eaau1184. https://doi.org/10.1126/science.aau1184
21. Katzman, J. G., Comerci Jr, G., Boyle, J. F., Duhigg, D., Shelley, B., Olivas, C., ... & Arora, S. (2014). Innovative telementoring for pain management: project ECHO pain. *Journal of Continuing Education in the Health Professions*, *34*(1), 68-75. DOI: 10.1002/chp.21210
22. Kennedy, J., Roll, J. M., Schraudner, T., Murphy, S., & McPherson, S. (2014). Prevalence of persistent pain in the US adult population: new data from the 2010 national health interview survey. *The Journal of Pain*, *15*(10), 979-984. https://doi.org/10.1016/j.jpain.2014.05.009
23. Kroenke, K., Stump, T. E., Kean, J., Krebs, E. E., Damush, T. M., Bair, M. J., & Monahan, P. O. (2021). Diagnostic operating characteristics of PROMIS scales in screening for depression. *Journal of Psychosomatic Research*, *147*, 110532. https://doi.org/10.1016/j.jpsychores.2021.110532
24. Manchikanti, L., Kaye, A. M., Knezevic, N. N., McAnally, H., Trescot, A. M., Blank, S., ... & Helm, S. (2017). Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) guidelines. *Pain physician*, *20*(2), S3. https://scholarlycommons.pacific.edu/phs-facarticles/647
25. Ozturk, O., Hong, Y., McDermott, S., & Turk, M. (2021). Prescription drug monitoring programs and opioid prescriptions for disability conditions. *Applied Health Economics and Health Policy*, *19*(3), 415-428. https://doi.org/10.1007/s40258-020-00622-4
26. Qaseem, A., Wilt, T. J., McLean, R. M., Forciea, M. A., & Clinical Guidelines Committee of the American College of Physicians*. (2017). Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. *Annals of internal medicine*, *166*(7), 514-530. https://doi.org/10.7326/M16-2367
27. Rosenberg, J. M., Bilka, B. M., Wilson, S. M., & Spevak, C. (2018). Opioid therapy for chronic pain: overview of the 2017 US Department of Veterans Affairs and US Department of Defense Clinical Practice Guideline. *Pain Medicine*, *19*(5), 928-941. https://doi.org/10.1093/pm/pnx203
28. Rossen, L. M., Hedegaard, H., Warner, M., Ahmad, F. B., & Sutton, P. D. (2021). Early provisional estimates of drug overdose, suicide, and transportation-related deaths: Nowcasting methods to account for reporting lags. https://www.cdc.gov/nchs/products/index.htm.
29. Rossom, R. C., Crain, A. L., O'Connor, P. J., Wright, E., Haller, I. V., Hooker, S. A., ... & Bart, G. (2023). Design of a pragmatic clinical trial to improve screening and treatment for opioid use disorder in primary care. *Contemporary clinical trials*, *124*, 107012. https://doi.org/10.1016/j.cct.2022.107012
30. Singer, M., Bulled, N., Ostrach, B., & Lerman Ginzburg, S. (2021). Syndemics: A cross-disciplinary approach to complex epidemic events like COVID-19. *Annual Review of Anthropology*, *50*(1), 41-58. https://doi.org/10.1146/annurev-anthro-100919-121009
31. Smith, N. Z., Thornton, J. D., Fenton, S. H., Simmons, D., & Champagne-Langabeer, T. (2023). Helpful, unnecessary, or harmful: a systematic review of the effects of prescription drug monitoring program use on opioid prescriptions. *Pharmacoepidemiology*, *2*(4), 350-365. https://doi.org/10.3390/pharma2040030
32. Volkow, N. D., & McLellan, A. T. (2016). Opioid abuse in chronic pain—misconceptions and mitigation strategies. *New England Journal of Medicine*, *374*(13), 1253-1263. DOI: 10.1056/NEJMra1507771.